06/06/2026
The data lands at 1:30 PM Central today in Chicago.
Retatrutide — a brand new triple-agonist from Lilly — posted 70.3 pounds of average weight loss at 80 weeks in its Phase 3 TRIUMPH-1 trial. Almost half the patients lost more than 30% of their body weight. These are numbers we have never seen before in an obesity drug.
But here is what is getting buried in the headlines: retatrutide is INVESTIGATIONAL. You cannot legally buy it. It is not approved anywhere in the world. Not in compounded form. Not in research vials. Not from your telehealth provider. Not from a peptide site. If someone is offering it to you this weekend — you are being sold a fake.
The gold standard rule still applies: a state-licensed 503A or 503B pharmacy, with the API on the FDA shortage list. That's it. That's the list.
My honest question for you — if a friend texted you tomorrow saying "I just got retatrutide vials, want some?" — what would you say back? Drop your reply below. No judgment. I am asking because I think a lot of people are about to be hustled this week.
(Education, not medical advice. Talk to your own clinician before changing any medication.)